Dentsply Sirona Inc Stock Price, News & Analysis

Dentsply Sirona (Nasdaq: XRAY) announced a revised date for its first quarter 2022 earnings conference call, now scheduled for May 10, 2022, at 8:30 am ET, moving from the previously set date of May 5. The call will be accessible via a live webcast on the Investors section of the company's website. A presentation related to the call will be published online, and a replay will be available for a week post-call. As the largest manufacturer of dental products, Dentsply Sirona continues to focus on innovation and effective solutions for patient care.

WellAir announced the appointment of Kari Dixon as President and CEO, effective immediately, succeeding Todd M. Pope, who will serve as Vice-Chair of the Board. Dixon, previously WellAir's CFO, possesses extensive experience in capital markets and financial planning, having worked with Dentsply Sirona and Form Technologies. Todd highlighted WellAir's advancements, including the launch of the FDA cleared Defend 400 air cleaning solution. Dixon aims to drive growth in the indoor air quality sector, emphasizing its significance in community wellness.

Dentsply Sirona has appointed John Groetelaars as Interim CEO following the termination of Don Casey. The Board is actively seeking a new CEO with a focus on driving operational excellence. Additionally, Barbara Bodem has been named Interim CFO to ensure a smooth transition after the departure of Jorge Gomez. Dentsply Sirona anticipates first quarter net sales of approximately $965 million, indicating a 1.4% decline year-over-year, affected by weaker U.S. sales and supply chain challenges. Further financial details will be disclosed on May 5, 2022.

Dentsply Sirona (Nasdaq: XRAY) has announced the resignation of Chief Financial Officer Jorge Gomez, effective May 6, 2022. Gomez, who joined the company in 2019, will take on a CFO role at another public company. The firm is now beginning the search for his replacement. CEO Don Casey expressed gratitude for Gomez’s contributions, notably in enhancing the Finance and IT sectors and improving the company's ESG initiatives. Dentsply Sirona maintains its status as the largest manufacturer of dental products and technologies worldwide.

Dentsply Sirona (Nasdaq: XRAY) has appointed John P. Groetelaars to its Board of Directors, expanding the board from eleven to twelve members. Groetelaars brings over 30 years of experience in MedTech, including his role as former CEO of Hillrom, where he led a $3 billion revenue organization. His leadership in transforming business strategies and promoting diversity initiatives positions him as a valuable asset to the board. Dentsply Sirona aims to enhance patient care through innovative dental solutions with his guidance.

Dentsply Sirona (Nasdaq: XRAY) will host an investor conference call on May 5, 2022, at 8:30 am ET to discuss its financial results. Investors can access a presentation on the company's website. The live webcast will also be available through the Investors section. Participants can join by dialing +1-877-370-7637 for domestic or +1-629-228-0723 for international calls, using Conference ID # 7888396. A replay will be accessible for one week post-call. Dentsply Sirona is a leading global manufacturer of dental products, known for its commitment to innovation and quality.

Dentsply Sirona, the world’s largest manufacturer of dental products, will participate in the Piper Sandler Virtual Dental Day. CEO Don Casey will lead a fireside chat on March 29, 2022, at 1:00 pm ET. The event will be accessible via a live webcast on the Dentsply Sirona Investors website. A replay will be available for 30 days post-discussion. Dentsply Sirona, listed on Nasdaq under the symbol XRAY, has a rich 135-year heritage in dental innovation, providing high-quality products to enhance patient care.

Dentsply Sirona (NASDAQ: XRAY) announced an accelerated share repurchase agreement totaling $150 million with Bank of America to repurchase its common stock. The initial delivery will be approximately 2.4 million shares, with final share count depending on the average stock prices during the valuation period. The ASR is expected to conclude by the end of Q2 2022, pending acceleration adjustments. This move aims to enhance shareholder value within Dentsply Sirona's current buyback authorization.

Dentsply Sirona reported strong FY21 results, with net sales of $4,251 million, a 27.2% increase year-over-year. Operating income rose to $622 million, and adjusted EPS reached $2.87, up 60.3%. However, Q4 sales were flat at $1,088 million, with adjusted EPS dropping 12.6% to $0.76. For FY22, the company forecasts organic sales growth of 4% to 5% and adjusted EPS between $3.05 and $3.25. CEO Don Casey emphasized their optimistic outlook based on a robust innovation pipeline and strategic partnerships.